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Group I metabotropic glutamate (mGlu) receptors consists of mGlu1 and mGlu5
receptor subtypes. These receptors are widely distributed in the central nervous system
(CNS), where they preferentially mediate facilitatory signaling in neurones and glial
cells, mainly by favoring phospholipase (PLC) translocation. Based on the literature
so far available, group I Metabotropic glutamate receptors (mGluRs) are preferentially
expressed at the postsynaptic side of chemical synapsis, where they participate in
the progression of the chemical stimulus. Studies, however, have shown the presence
of these receptors also at the presynaptic level, where they exert several functions,
including the modulation of transmitter exocytosis. Presynaptic Group I mGluRs can
be both autoreceptors regulating release of glutamate and heteroreceptors regulating
the release of various transmitters, including GABA, dopamine, noradrenaline, and
acetylcholine. While the existence of presynaptic release-regulating mGlu5 receptors
is largely recognized, the possibility that mGlu1 receptors also are present at this level
has been a matter of discussion for a long time. A large body of evidence published in
the last decade, however, supports this notion. This review aims at revisiting the data
from in vitro studies concerning the existence and the role of release-regulating mGlu1
receptors presynaptically located in nerve terminals isolated from selected regions of the
CNS. The functional interaction linking mGlu5 and mGlu1 receptor subtypes at nerve
terminals and their relative contributions as modulators of central transmission will also
be discussed. We apologize in advance for omission in our coverage of the existing
literature.
Keywords: mGlu1 receptors, transmitter release, autoreceptors, heteroreceptors, presynaptic receptors
THE PRESYNAPTIC CONTROL OF TRANSMITTER RELEASE
Transmitter release is a key event of central transmission. At chemical synapsis, it assures the
transmission from the presynaptic to the postsynaptic component of the active synapse, allowing
the propagation of the stimulus. The transfer of chemical information from the pre- to the
postsynaptic components of the active synapses is mediated by transmitter(s) actively released
by the presynaptic side of the synapsis acting at receptors postsynaptically located. Once into the
biophase, transmitter(s) also act retrogradely, at receptors located at the synaptic boutons from
which they are released, as well as at neighboring terminals. The former ones are called presynaptic
receptors and are located within the active zone, while those located close to the synaptic active
zone, where vesicular transmitter exit occurs, are referred to as perisynaptic receptors.
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Chemical transmission also occurs at neuronal processes
that fail to make synaptic contacts. In this case, the non-
synaptic compartment senses transmitter release from nerve
endings through a mechanism of non-synaptic communication
or “volume transmission” (Vizi et al., 2010). The targets of
transmitters that diffuse through the “volume transmission”
are receptors located at the “non-synaptic release sites,” i.e.,
those receptors located extrasynaptically (although also receptors
existing at the perisynaptic side have been included in this group,
Vizi et al., 2010). These “non-synaptic” receptors are located
postsynaptically with respect to nerve terminals releasing the
transmitter from which they are activated, but they are located
presynaptically at nerve edges or varicosities, where they exert
their functional effects, including the modulation of transmitter
release (Figure 1).
At both the synaptic and the non-synaptic sites, depending on
the natural ligand that activates the release-regulating receptors,
we can distinguish between auto- and heteroreceptors, the
former controlling the release of their natural agonist, the latter
controlling the release of transmitters other than their natural
ligand. Release-regulating receptors can be further classified in
negative and positive receptors. Presynaptic negative receptors
counter-balance the increased availability of transmitter(s), while
presynaptic positive receptors, in particular the autoreceptors,
amplify it, then favoring synaptic plasticity, but, if excessive,
leading to overt excitotoxicity. Drugs targeting these receptors
are suitable candidates as therapeutic agents for restoring altered
central neurotransmission.
Of the characterized release-regulating presynaptic receptor
systems, the glutamatergic one is particularly complex. Although
both ionotropic and metabotropic glutamate (mGlu) receptors
modulate transmitter exocytosis, mGlu auto and heteroreceptors
predominate as release controllers (Cartmell and Schoepp, 2000;
Schoepp, 2001). Metabotropic glutamate receptors (mGluRs)
belong to the family 3 of the G protein coupled receptors
(GPCRs). By triggering intraterminal enzymatic pathways
leading to activation of phosphorylative processes, the group I
mGlu receptors positively control the molecular events occurring
at nerve terminals. In particular, besides the control of transmitter
exocytosis, they can regulate the insertion/internalization of the
AMPA and NMDA receptor subunits, determining changes in
the subunit composition and, consequently, in receptor-mediated
functions. Their structures and activity has been matter of
discussion in several reviews (Pin and Bockaert, 1995; Nicoletti
et al., 1999, 2011, 2015; Bruno et al., 2001) and will not be further
analyzed here.
THE UP–DOWN SUPERFUSION OF A
THIN LAYER OF SYNAPTOSOMES:
SOME EXPERIMENTAL
CONSIDERATIONS
In the last decade, great effort has been invested to elucidate
whether mGlu1 receptors exist at the presynaptic level and
what the functional consequences of their activation are. The
FIGURE 1 | Synaptic and non-synaptic communications in the central
nervous system. (A) Synaptic communication in central nervous system.
Synaptic contacts between nerve endings originating from distinct neurons
are organized in chemical synapsis where the presynaptic component
releases the transmitter in the synaptic cleft. Once released, the transmitter
can act at receptors located at the postsynaptic side of the synapses (black
and purple receptors) as well as at autoreceptors located at the presynaptic
side (blue and red ones). The transmitter also can target receptors that are
located perisynaptically, out of the synaptic active zone (the green and orange
receptors). (B) Non-synaptic communication in CNS. Nerve terminals also
could be connected non-synaptically one to each other. The nerve terminal
boutons from the bright green neurons do not make synaptic contact with
those originating from the red ones, but they can influence the functions of the
latter terminals through the mechanism of the “volume diffusion.” The
receptors located on the red terminals are extrasynaptic receptors that are
postsynaptically located with respect to the bright green nerve terminals but
that are located presynaptically with respect to the red terminals.
majority of the studies were carried out by using synaptosomes
in superfusion to monitor transmitter release so that, before
focussing on the topic of this review, it seems useful to recall some
of the main features of this experimental approach.
Many authors believe that the simplest and well-established
model for studying release-regulating receptors is the isolated
nerve terminal (synaptosome) preparation. Synaptosomes are
freshly isolated nerve terminals that maintain all the functional
properties of the originating nerve terminals/varicosities, since
they can synthesize, store, release, and re-uptake transmitters.
They are endowed with native receptors and transporters, with
enzymes and G proteins and contain the cytosolic machinery
so that: (i) they synthesize and store transmitters; (ii) they
store newly uptaken molecules; (iii) they release transmitters in
an exocytotic-like or in a carrier-mediated manner, (iv) they
enable physical interaction and functional cross-talk among co-
localized receptor proteins, as well as the insertion and deletion
of receptor proteins from – to synaptic membranes (v) they favor
the transduction of G protein-induced signaling and develop
enzymatic processes.
Synaptosomes are isolated from tissue homogenates by
centrifugation and then purified on a Percoll gradient to
eliminate contaminating particles originating from other cells,
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including astrocytes. This is particularly relevant in studies
dedicated to the pharmacological characterization of presynaptic
mGlu1 autoreceptors modulating glutamate release from nerve
endings. Actually, although the existence of mGlu1 receptors
in astrocytes is matter of discussion (Spampinato et al., 2012
and references therein), the possibility that these receptors
are expressed in gliosomes (i.e., particles originating from
astrocyte arborisations during tissue homogenisation to isolate
synaptosomes, Milanese et al., 2009) deserves attention. If
present, glial mGlu1 receptors could elicit glutamate release, then
indirectly altering the efficiency of glutamate exocytosis from the
synaptosomal suspension. The purification on a Percoll gradient
(Dunkley et al., 1986) drastically reduces glial contamination
(Milanese et al., 2010), preventing these artifacts.
Raiteri et al. (1974) described for the first time the so-called
“up-down superfusion of a thin layer of synaptosomes,” an
experimental approach to monitor the release of transmitter from
these particles (Raiteri et al., 1974). This technique is nowadays
considered a method of choice for the study of presynaptic
mechanisms. Two were the main innovations introduced:
(i) Synaptosomes were continuously up-down superfused with
a medium thermostated at 37◦C having an isoosmotic and
isotonic ionic composition with these particles.
(ii) Synaptosomes were layered as a monolayer on porous filters
at the bottom of thermostated chambers.
These innovations assure the almost-complete absence of
biophase and, as a consequence, of indirect effects. Actually,
during superfusion, the endogenous compounds are immediately
removed, so that their concentration at nerve terminals is
minimized and the possibility that they can act on adjacent
particles is largely impeded. Inasmuch, the stratification of
synaptosomes as a monolayer impedes the possibility that
the endogenous molecules can act at synaptosomes located
below those particles from which they are released. In these
conditions, receptor-mediated changes to the transmitter release
can only be elicited by compounds exogenously added at the
superfusion medium, which activates the receptors in selected
synaptosomal subpopulations (Figure 2). In particular, agonist-
induced control of transmitter outflows can be evidentiated
directly, as drug-mediated changes of exocytosis. Differently, the
ability of antagonist(s) to modulate release is mainly highlighted
as reversal of the agonist-induced releasing effects.
The synaptosomal suspension originating from a selected
central nervous system (CNS) region is composed of
particles that are isolated from different subfamilies of
nerve endings. The selective labeling with radioactive tracers
mimicking endogenous transmitters (i.e., [3H]noradrenaline;
[3H]dopamine; [3H]serotonin; [3H]GABA) as well as the
monitoring of the release of endogenous molecules (glutamate,
GABA, glycine, and neuropeptides) permits to isolate a given
sub-family of nerve terminals from the entire synaptosomal
FIGURE 2 | The superfusion apparatus consists of several (up to 24) units composed of an upper reservoir (A) where the medium is thermostated up
to 37◦C and from which it is rapidly delivered to the lower chamber of superfusion (B). Synaptosomes are stratified as a monolayer on micro-porous filter
(C). In the lower chamber, the superfusion medium is continuously recalled by means of a peristaltic pump. The continuous up-down superfusion assures the rapid
removal of any endogenous compounds that is actively released from the stratified particles so that any indirect effects is minimized (D). In these experimental
conditions receptors only can be activated by molecules exogenously added to the superfusion medium (red triangles).
Frontiers in Pharmacology | www.frontiersin.org 3 August 2016 | Volume 7 | Article 295
fphar-07-00295 August 31, 2016 Time: 11:56 # 4
Pittaluga Presynaptic Release Regulating mGlu1 Receptors
populations, impeding artifacts that may originate from the
heterogeneity of the synaptosomal preparation.
By using this experimental approach, the following functional
aspects could be investigated:
(1) The existence and the functional role of release-
regulating receptors in nerve terminals as well as their
pharmacological profile/subunit composition can be
defined. These aspects have been extensively discussed in
previous reviews (Raiteri and Raiteri, 2000) and do not
need further discussion.
(2) The receptors co-localization and receptor-receptor
functional cross-talk (Marchi and Grilli, 2010; Grilli et al.,
2012; Marchi et al., 2014, 2015).
(3) The existence of metabotropic receptors adopting a
constitutively activated conformation. This conformation
can transduce intraterminal signallings despite the absence
of agonist at the orthosteric binding site of the receptors
(see Presynaptic Release-Regulating mGlu1 Autoreceptors
in Mouse Cerebellar Nerve Endings and Presynaptic mGlu1
Heteroreceptors and Dopamine Release from Rat Nerve
Endings, Mura et al., 2010; Rossi et al., 2013).
(4) The functional activity of positive and negative allosteric
modulators (PAM and NAM) acting at both ionotropic
and metabotropic receptors. The classic example of PAM
is glycine acting at NMDA receptors controlling the
release of noradrenaline and dopamine (Pittaluga et al.,
2001), peptides (Gemignani et al., 2000) and glutamate
(Luccini et al., 2007b; Musante et al., 2011) terminals.
Similarly, cyclothiazide favors the AMPA-evoked release
of serotonin, dopamine, and noradrenaline (Pittaluga
et al., 1997). Last, but not least, the mGlu5 PAM,
the compound [(3-Fluorophenyl)methylene]hydrazone-3-
fluorobenzaldehyde (DFB), was shown to amplify the
mGlu5-mediated potentiation of noradrenaline exocytosis
(Luccini et al., 2007a).
(5) The pharmacological profile of molecules having a complex
pharmacological profile can be identified. It is the case of
the double-faced mGlu2/3 ligand the compound LY541850,
which activates mGlu2 receptor subtypes but inhibits
mGlu3 receptors (Di Prisco et al., 2016).
MGLU1 AUTORECEPTORS IN CENTRAL
NERVOUS SYSTEM
Presynaptic Release-Regulating mGlu1
Autoreceptors in Mouse Cortical Nerve
Endings
The first work concerning the existence of group I mGlu
autoreceptors in cerebrocortical synaptosomes was by Herrero
et al. (1992, 1994), who showed that the glutamate release elicited
by 50 µM 4-aminopyridine (4-AP), in the presence of low
concentrations of arachidonic acid, was significantly increased by
the broad group I mGluR agonist (1S,3R)-1-Aminocyclopentane-
1,3-dicarboxylic acid (1S,3R)-ACPD (Table 1).
Starting from these observations, the exact identity of the
autoreceptors belonging to the group I mGlu receptors (whether
mGlu1 receptors or mGlu5 receptors or both) became a matter
of discussion. The question, however, has long remained elusive,
mainly due to the lack of selective ligands. Similarly, the
presynaptic location of these receptors was debated because
of contradictory results in the literature (Fotuhi et al., 1993;
Shigemoto et al., 1993; Romano et al., 1995; Lujan et al., 1996;
Hubert et al., 2001; Muly et al., 2003). Most of these publications,
however, agreed on the presence of mGlu5 autoreceptors in
nerve terminals isolated from different CNS regions of mammals
(Sistiaga et al., 1998; Croucher et al., 2001).
As to the mGlu1 receptor subtype, the hypothesis that
these receptors also could have a presynaptic location on
glutamate nerve endings was first proposed by Reid et al.
(1999). Reid et al. (1999) pharmacologically characterized
the group I mGlu autoreceptors in cortical synaptosomes.
The most interesting observation was that (RS)-2-Chloro-
5-hydroxyphenylglycine (CHPG, Table 1), a preferential
mGlu5 receptor agonist, failed to potentiate the 4-AP-evoked
[3H]glutamate release from cerebrocortical synaptosomes,
while the selective mGluR1 antagonist (RS)-1-Aminoindan-1,5-
dicarboxylic acid (AIDA, Table 1) abolished the potentiation
elicited by the mGlu1/5 broad spectrum agonist, the compound
(S)-3,5-Dihydroxyphenylglycine (3,5-DHPG, Table 1). These
results led to propose that presynaptic mGlu5 receptors did not
account for the functional responses observed, but that the group
I mGlu receptors under study belonged to the mGlu1 receptors
subtype. These observations were largely confirmatory of
previous results obtained in microdialysis studies in the parietal
cortex of rats showing a significant increases of glutamate
release following local administration of both (1S,3R)-ACPD
and 3,5-DHPG (Moroni et al., 1998). AIDA, inactive on its
own, antagonized the effect of the group I mGluR agonist. The
hypothesis of the presynaptic location of mGlu1 receptors, was,
however, contrasted by the almost concomitant findings from
Sistiaga et al. (1998), showing that the 3,5-DHPG potentiation
of glutamate exocytosis could be observed in cortical nerve
terminals isolated from mGlu1 receptors-deficient mice. Based
on these findings, the authors excluded that mGlu1 autoreceptors
could be present in mouse cortical nerve endings. In line with
this conclusion, Croucher’s group demonstrated that the 3,5-
DHPG-induced facilitation of [3H]D-aspartate ([3H]D-ASP)
release in slices was largely insensitive to mGlu1 receptors
antagonists, but it was potently antagonized by selective mGlu5
receptors blockers (Thomas et al., 2000; Croucher et al., 2001;
Fazal et al., 2003).
The question concerning the existence and the role of mGlu1
autoreceptors was reconsidered by Musante et al. (2008b). Using
the technique of the up–down superfusion of synaptosomes,
these researchers confirmed that 3,5-DHPG, inactive on its own
on the spontaneous release of [3H]D-ASP, significantly facilitated
the exocytosis of the radioactive tracer elicited by a mild (12 mM
KCl) depolarizing stimulus from mouse cortical synaptosomes.
Quite interestingly, the analysis of the concentration-effect
relationship of the agonist on the [3H]D-ASP exocytosis unveiled
a biphasic pattern, where peaks of potentiation were reached
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TABLE 1 | Pharmacological properties of the mGlu1 and mGlu5 receptor ligands reported in the text.
Ligand Pharmacological activity Reported affinity (units) Pharmacological properties Applied concentration (µM)
(1S,3R)ACPD mGlu1/5 receptor full agonist 5.5–6.1 (pIC50) ↑ Transmitter release 100–1000
(RS)CHPG mGlu5 agonist 3.4 (pIC50) ↑ Transmitter release 10–300
3,5 DHPG mGlu1/5 receptor full agonist 5.4–5.8 (pIC50) ↑ Transmitter release 0.01–100
MPEP mGlu5 non-competitive antagonist 7.4–7.7 (pIC50) ↓ 3,5 DHPG-evoked transmitter release 0.1–1
CPCCOEt mGlu1 non-competitive antagonist 5.3 (pKi) ↓3,5 DHPG-evoked transmitter release 1–5
LY367385 mGlu1 competitive antagonist 5.9 (pKi) ↓ 3,5 DHPG-evoked transmitter release 0.1–10
The table recapitulates the principal properties of the main mGlu1 and mGlu5 receptor ligands reported in the review. The reported affinity are accordingly to IUPHAR/BPS
Guide to PHARMACOLOGY.
when low (0.3 µM) and high (30–50 µM) concentrations of
the agonist were applied. Intermediate concentrations elicited
a scarce, not significant, facilitation of glutamate exocytosis.
The dual effect seemed predictive of the existence of high-
and low-affinity binding sites for the agonist. Notably, the
3,5-DHPG-mediated facilitation of glutamate exocytosis
elicited by low (0.3 µM) concentration of the agonist (i.e.,
the high-affinity binding site) was prevented by 2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP, Table 1), while
the compound 7-(Hydroxyimino)cyclopropa[b]chromen-1a-
carboxylate ethyl ester (CPCCOEt, Table 1) was inactive; this
is compatible with the involvement of mGlu5 autoreceptors.
Differently, the positive effect exerted by higher (i.e., 30 µM)
concentration of the agonist (the low affinity binding site)
was almost insensitive to MPEP, but it was totally prevented
by CPCCOEt, suggesting that mGlu1 autoreceptors play a
major role. To conclude, these observations confirmed the
presence of high-affinity mGlu5 autoreceptors in mouse cortical
nerve endings (as already proposed in literature, Sistiaga et al.,
1998; Croucher et al., 2001), but also strongly suggested the
presence of low-affinity mGlu1 autoreceptors. Accordingly, the
MPEP-sensitive, 3,5-DHPG-mediated facilitation of glutamate
exocytosis became undetectable in synaptosomes isolated from
the cortex of a transgenic mouse lacking the mGlu5 receptor
protein; while the CPCCOEt-sensitive, 3,5-DHPG-mediated
facilitation of glutamate exocytosis was undetectable in cortical
synaptosomes from mice bearing a spontaneous deletion of
the mGlu1 receptor protein (i.e., the crv4/4 mice, Conti et al.,
2006).
Metabotropic glutamate1 and mGlu5 receptors are positively
coupled to PLC and elicit diacyl glycerol (DAG) and inositol
trisphosphate (IP3) production. Data in the literature had
shown that activation of phosphoinositide (PI)-coupled mGlu
receptors potentiates the release of glutamate (Herrero et al.,
1992; Vazquez et al., 1994), through a DAG/PKC-mediated
intraterminal pathway (Coffey et al., 1994; Herrero et al., 1994,
1998). Using a mGluR1 deficient mouse model (Conquet et al.,
1994). Sistiaga et al. (1998) indicated that nerve terminals
isolated from the cortex exhibit all the responses of the PI-
coupled mGluRs observed in wild type mice, including the DAG
overproduction and the glutamate exocytosis induced by DHPG.
Based on these observations, the authors proposed that mGlu5
receptor subtypes, or an unidentified PI-coupled mGlu receptor,
could best account for the modulation of glutamate release
in mouse cerebro-cortical nerve terminals. The possibility that
mGlu1 receptors could participate in the effects above described,
however, was not ruled out. More recently, mouse cortical
synaptosomes were analyzed for their endogenous inositol-1,4,5-
trisphosphate (IP3) content following the exposure to a mild
depolarizing stimulus in the absence or in the presence of 3,5-
DHPG / MPEP (the antagonist was added in order to impede
the mGlu5-mediated metabolic effects). The data demonstrated
that the mGlu1/5 receptor agonist facilitated the 12 mM K+-
evoked production of endogenous IP3 and that this facilitation
was significantly prevented by CPCCOEt. This is consistent
with the participation of the mGlu1-induced signaling in the
overproduction of the intraterminal second messenger (Musante
et al., 2010). Thus, mGlu1 autoreceptors in mouse cortical nerve
endings are positively coupled to an enzymatic pathway leading
to IP3 overproduction and the consequent release of Ca2+ ions
from intraterminal stores. Whether the mGlu1/5 receptor agonist
could trigger the release of endogenous IP3 also in the absence
of the depolarizing stimulus was not investigated. 3,5-DHPG,
however, failed to modify the spontaneous release of glutamate,
suggesting that, if a mGlu1/5-induced mobilization of Ca2+ ions
had occurred in mouse cortical nerve endings, this event was
insufficient to elicit glutamate outflow (see Presynaptic mGlu1
Heteroreceptors and Acetylcholine Release from Human Cortical
Nerve Endings).
To substantiate these functional results, subsequent
experiments were carried out to investigate whether
mGlu1 receptor immunoreactivity exists in mouse cortical
synaptosomes. As a first approach, the existence of mGlu1
immunoreactivity in the detergent-soluble fraction isolated
from cortical synaptosomes was analyzed. Accordingly to
expectation, it was found that synaptosomal lysates are
immunopositive for both the mGlu1 and the mGlu5 receptor
proteins (Musante et al., 2008b). The synaptosomal fraction used
in these experiments, however, contains all the synaptosomal
membrane proteins, including those from the organelles and
vesicles, as well as those from the postsynaptic membrane
fragments that are often sealed to the synaptic boutons during
synaptosomes preparations and it did not allow to discriminate
between the mGlu receptor proteins located presynaptic or
postsynaptically. To definitively address this question, an
experimental approach of synaptosomal subfractioning to
isolate the pre- and the post-synaptic components of the
synaptic active zone was applied. The separation of the two
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components was validated by analyzing the immunoreactivities
of proteins that are considered specific markers of the three
synaptosomal fractions (i.e., syntaxin1-A for the presynaptic
component and, PSD-95 for the postsynaptic component,
Musante et al., 2008b). These experiments confirmed the
presynaptic location of the mGlu1 receptor protein, showing
that, in addition to mGlu5, mGlu1 receptor immunoreactivity
was detectable in the Sintaxin-1A positive presynaptic fraction.
mGlu1 immunoreactivity was also observed in the PSD-
95-positive, postsynaptic component, which is consistent
with the proposed localization of mGlu1 receptors at this
side of the active synapses (Ferraguti et al., 2008). Finally,
considering that the abovementioned approaches do not
allow to discriminate among families of nerve terminals,
experiments were carried out to ascertain whether mGlu1
immunoreactivity could be detected in glutamatergic nerve
endings. Immunochemical studies demonstrated that both
receptor proteins were largely co-expressed with Sintaxin1-A
used as a selective presynaptic marker and with the vesicular
glutamate transporter type 1 protein (VGLUT-1), used as a
selective marker of glutamatergic nerve endings. To conclude,
these data were largely confirmatory of the existence of mGlu5
autoreceptors on cortical glutamatergic nerve endings, but
also supported the existence of mGlu1 autoreceptors on these
terminals.
However, it is not clear whether the two mGlu5 and mGlu1
receptors co-localize on the same terminals, or whether they
exist on different nerve endings. Albeit the question cannot be
definitively answered, some speculation can be proposed on the
basis of the data so far available.
The most conservative hypothesis maintains that the mGlu1
and the mGlu5 receptors exist on different subpopulations of
cortical glutamatergic nerve terminals. If true, this hypothesis
implies that the releasing effects elicited by the two receptors
are additive. This, however, was not the case of the mGlu1
and 5 autoreceptors controlling glutamate exocytosis in mouse
cortex. Actually, the concentration-response curve of 3,5-DHPG
displays a biphasic pattern (Figure 3) that seems best interpreted
by assuming the colocalization and the functional cooperation
of a high-affinity mGlu5 and a low-affinity mGlu1 receptor.
This is consistent with recent data suggesting that mGlu
receptors can exist either as homomeric or heterodimeric
assemblies as well as inter-dimeric complexes (Doumazane
et al., 2010). The observation that anti-mGlu1 and anti-mGlu5
immunoprecipitates from mouse cortical synaptosomes were
immunopositive for the mGlu5 receptor protein and the mGlu1
receptor protein, respectively (Musante et al., 2010), seems in
line with the proposed mGlu1 and mGlu5 physical interaction.
Furthermore, the orthosteric mGlu1 receptor antagonist, the
compound (S)-(+)-α-Amino-4-carboxy-2-methylbenzeneacetic
FIGURE 3 | mGlu1 and mGlu5 receptors co-localize and functionally interact in mouse cortical glutamatergic nerve endings. mGlu5 receptors (red
external domains) represent the high affinity agonist binding sites of the agonist, which is fully activated when synaptosomes are exposed at concentration of
3,5-DHPG as low as 0.3 µM; ∗p < 0.05 vs. control (empty bar). (A) The occupancy of the orthosteric binding sites of these receptors leads to an overt potentiation
of glutamate exocytosis. Increasing the external concentration of the agonist, however, also allows the occupancy of the mGlu1 receptors (green external domains)
(B). These receptors represent the low affinity binding sites of the agonist and their orthosteric binding sites are fully activated when synaptosomes are exposed at
concentration of 3,5-DHPG as high as 30 µM. The exposure of cortical glutamatergic nerve terminals to intermediate concentration of 3,5-DHPG (3 µM) allows the
partial occupancy of the orthosteric binding sites of the mGlu1 receptors. We propose that when exposed at concentration of 3,5-DHPG as low as 3 µM, the partial
occupancy of the mGlu1 agonist binding sites can negatively reverberate on the mGlu5 receptor component of the mGlu1/mGlu5 receptor/receptor complex,
leading to the falls of efficiency of the agonist to potentiate glutamate exocytosis (C). The further increase of the concentration of 3,5-DHPG assures the full
occupancy of the orthosteric binding sites in both the receptors, unveiling the maximal facilitation of glutamate exocytosis; ∗∗p < 0.01 vs. control (empty bar) (D).
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acid (LY367385, Table 1), efficiently prevented the facilitation
of glutamate exocytosis elicited by 3,5-DHPG acting at mGlu1
autoreceptors (as indeed expected), but it also proficiently
reduced the potentiation of glutamate exocytosis caused by
low submicromolar concentration of agonist acting at mGlu5
receptors (Musante et al., 2008b). Again, this observation
strengthened the conclusion that the mGlu5 and the mGlu1
receptors are colocalized and possibly are functionally coupled.
Actually, since the data available exclude the possibility
that LY367385 acts at mGlu5 receptor subtypes, the most
conservative hypothesis is that the binding of the mGlu1 receptor
orthosteric antagonist at the mGlu1 receptor protein also might
activates compensative allosteric mechanism(s) of control of the
heterodimeric complex, influencing the efficiency of the binding
of the ligand at the other component, i.e., the high affinity mGlu5
receptor protein.
As a matter of fact, differently from the homodimeric
assembly, where the impact of the occupancy of the orthosteric
binding sites is allosteric to receptor-mediated functions and
not simply cumulative, in an heterodimeric complex, as well
as in inter-heterodimeric receptor assemblies, the binding of an
orthosteric ligand at one component controls either positively or
negatively the pharmacological profile of the other binding site,
thus leading to unexpected changes in the concentration-effect
relationship of the agonist (Delille et al., 2012).
To note, the functional interaction bridging mGlu1 and
mGlu5 receptor proteins might also give a rationale for the
reduced release efficiency observed when synaptosomes are
exposed at concentration of the agonist that are intermediate to
those eliciting the maximal releasing effects. For instance, the
partial occupancy of the mGlu1 component of the mGlu1/mGlu5
heterodimeric assembly might causes a transient unbalance of
the mGlu1/mGlu5 functional cross-talk (Figure 3) accounting for
the reduced the release efficiency. Further studies are required to
better address this hypothesis.
Presynaptic Release-Regulating mGlu1
Autoreceptors in Human Cortical Nerve
Endings
Preclinical studies of animal models have the potential to
identify therapeutic targets in humans. It is therefore essential to
determine whether corresponding proteins/molecular pathways
also exist in humans. The use of fresh human tissue removed
during neurosurgery endowed with native receptor proteins
and transporters represents a unique approach to evaluate the
pharmacological profile of the molecular structures identified
in rodents. This approach could lead to the identification of
molecular processes underlying the effects of therapeutics in
humans, but also consents the validation of the use of the animal
models for pharmacological studies.
The existence and the functional role of mGluR1
autoreceptors were investigated in human cortical synaptosomes.
The terminals were isolated from human fresh cortical specimens
that were removed during neurosurgery to reach deeply located
cerebral tumors (Feligioni et al., 2003; Luccini et al., 2007a;
Musante et al., 2008a). A study was carried out to verify the
existence and the functional role of mGlu1 autoreceptors
controlling [3H]D-Aspartate release, (Musante et al., 2010). It
was demonstrated that 3,5-DHPG in the presence of MPEP
(in order to exclude the release component due to the mGlu5
receptors activation) enhanced the K+-evoked release of the
excitatory amino acid, an effect that was totally abolished by
the mGlu1 receptors antagonist CPCCOEt (Musante et al.,
2010). Quite interestingly, the 3,5-DHPG releasing activity
was paralleled by an overproduction of endogenous IP3 in the
synaptosomal preparation, which was significantly prevented
by the concomitant addition of the mGlu1 receptor antagonist.
At the concentration applied, the agonist failed to affect the
spontaneous release of preloaded [3H]D-Asp; this is consistent
with the idea that in human cortical nerve terminals the
metabolic effect(s) elicited by the receptor was insufficient to
promote “per se” transmitter exocytosis. Finally, mGlu1 receptor
immunoreactivity was detected in the lysates from human
cortical nerve terminals (Musante et al., 2010). Altogether, these
observations allowed the following conclusions: (i) human
neocortical glutamatergic nerve endings are endowed with
release-regulating mGlu1 autoreceptors, the activation of which
favors glutamate exocytosis through a cascade of events that
promote the release of Ca2+ ions from intraterminal IP3-
sensitive stores; and (ii) mouse cortical glutamatergic nerve
endings are an appropriate model to predict the functional
activity of mGlu1 receptor bioactive compounds in humans.
Presynaptic Release-Regulating mGlu1
Autoreceptors in Mouse Hippocampal
Nerve Endings
At the hippocampal level, mGlu1 receptors have been implicated
in synaptic transmission and plasticity, neuronal excitability, and
firing synchronization (Ferraguti et al., 2008). The existence at
the presynaptic level of mGlu1 autoreceptors and their role in
controlling glutamate exocytosis in this CNS region is an ongoing
matter of discussion. The first demonstration of a potential
role of mGlu receptors belonging to the first group in the
facilitation of glutamate release from hippocampal terminals was
provided by Vazquez et al. (1994). These authors demonstrated
that the broad-spectrum agonist ACPD greatly potentiated the
Ca2+-dependent release of endogenous glutamate evoked by
a mild depolarization. Quite interestingly, the ACPD-induced
facilitation of glutamate exocytosis became detectable only when
arachidonic acid was added concomitantly to the depolarizing
stimulus. The positive allosteric activity elicited by the fatty
acid was proposed to rely on intraterminal facilitatory effect(s)
that paralleled the activation of the mGlu receptors complex.
Starting from 1994, using experimental approaches other than
synaptosomes, some indications of the respective roles of mGlu5
and mGlu1 receptors in controlling glutamate transmission were
provided. In the CA1 neurones of mGlu1-deficient mice, the
group I mGlu receptor agonist ACPD elicited excitatory effects
similar to those observed in control mice (Aiba et al., 1994;
Conquet et al., 1994), but not in mGlu5 deficient mice (Lu
et al., 1997; reviewed by Bordi and Ugolini, 1999). This latter
observation, however, was not confirmed in a subsequent study
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(Hsia et al., 1995). Inasmuch, in mGlu1 mutant mice, LTP in
the CA3 region was largely reduced (Conquet et al., 1994).
Concomitantly, Gereau and Conn (1995) proposed a presynaptic
role of mGlu receptors with a group I-like pharmacology in the
control of both excitatory and inhibitory synaptic transmissions
in the CA1 region. Similar results were obtained by Manzoni and
Bockaert (1995). The dual role of the group I mGlu receptors
on the release of glutamate in rat hippocampal synaptosomes
were then investigated by Rodriguez-Moreno et al. (1998, but
see also Vazquez et al., 1995). In an attempt to reconciliate both
facilitation and inhibition of glutamate exocytosis the authors
proposed that the mGlu-induced facilitation of glutamate release
elicited by mGlu receptors with a group I-like pharmacology
(Gereau and Conn, 1995) is desensitized by increasing the
ambient glutamate. This results from a shift of the coupling
of these receptors to an alternative inhibitory intraterminal
pathway. Few years later, Mannaioni et al. (1999), proposed that
the DHPG-induced increase of the neuron excitability in the
hippocampus is mainly due to activation of mGlu5 autoreceptors.
Soon after, mGlu1 receptors were also suggested to be located
presynaptically in selected regions of rat hippocampus, where
their activation suppresses, instead of potentiating, excitatory
transmission (Mannaioni et al., 2001). Finally, Smolders et al.
(2004) proposed the existence of mGlu1a autoreceptors tonically
activated by the ambient glutamate level in the hippocampus.
Further investigation is required to confirm the respective
contribution of mGlu5 and mGlu1 receptor subtypes to the
facilitation of glutamate exocytosis in this CNS region.
Presynaptic Release-Regulating mGlu1
Autoreceptors in Mouse Cerebellar
Nerve Endings
Although the literature remains controversial regarding the
existence of mGlu1 receptors in different CNS regions, there
is a large consensus on the dominant presence of mGlu1
receptors in the cerebellum. In this CNS region, mGlu1 receptors
immunoreactivity is mainly found at the excitatory inputs onto
Purkinje cells, particularly in the perisynaptic region of their
dendritic spines onto which climbing fibers and parallel fibers
make synaptic contact. At this level, however, little mGlu1
receptor expression was detected in parallel fiber terminals
(Nusser et al., 1994; Mateos et al., 2000), allowing the conclusion
that mGlu1 receptors are preferentially located postsynaptically
(Ferraguti et al., 2008). The postsynaptic mGlu1 receptors were
proposed to play the major role in controlling cerebellar LTD (Ito
and Kano, 1982; Linden and Connor, 1993; Ito, 2002).
Rossi et al. (2013), a study was carried out to investigate
whether mGlu receptors belonging to the first group control the
release of glutamate from cerebellar synaptosomes. Micromolar
3,5-DHPG failed to affect the spontaneous release of glutamate
(measured as release of preloaded [3H]D-aspartate) from mouse
cerebellar isolated nerve endings, but significantly potentiated
the Ca2+-dependent exocytosis of the radioactive tracer elicited
by a mild depolarizing stimulus (12 mM KCl). The 3,5-DHPG-
evoked facilitation of glutamate exocytosis was prevented by
the mGlu1 receptor antagonist CPCCOEt, while MPEP was
devoid of activity. Based on these functional observations, it
was proposed that mGlu1 autoreceptors exist in cerebellar
synaptosomes, and that their activation potentiates glutamate
exocytosis. Accordingly, (i) lysates from cerebellar synaptosomes
were found to be endowed with mGlu1 receptor proteins in
immunochemical studies, while the mGlu5 signaling was almost
absent, and (ii) the CPCCOEt-sensitive 3,5-DHPG-induced
facilitation of glutamate exocytosis could not be observed in the
crv4/4 mice (Conti et al., 2006). Taking into account that the
synaptosomal population isolated from the cerebellum mainly
consists of pinched off particles from parallel fiber boutons,
and to a lower extent, from climbing fiber terminals (Cervetto
et al., 2010), it is possible that mGlu1 receptors are mainly
expressed in parallel fibers processes. The results obtained in
immunocytochemical studies aimed at dissecting the respective
localization (presynaptic vs. postsynaptic) of the mGlu1 receptor
protein at the parallel fibers – Purkinje cells synapses (see
Ferraguti et al., 2008 for discussion), however, contrast this
conclusion. Further studies are needed to better address this
point.
Surprisingly, the mGlu1 allosteric antagonist CPCCOEt
significantly reduced on its own the 12 mM KCl-evoked
exocytosis of preloaded [3H]D-aspartate. The observation was
unexpected since in the up–down superfusion model, antagonists
are predicted to be devoid of activity and to be unable to
control transmitter release (The Up–Down Superfusion of a Thin
Layer of Synaptosomes: Some Experimental Considerations).
The inhibitory effect exerted by CPCCOEt on the depolarization-
evoked glutamate outflow was not observed in synaptosomes
isolated from the cerebellum of mouse lacking the mGlu1
receptor proteins (i.e., the crv4/4 mice, Conti et al., 2006), thus
supporting the conclusion that mGlu1 receptors were involved
in the CPCCOEt-mediated control of glutamate exocytosis.
Inasmuch, the amount of glutamate released from cerebellar
terminals isolated from crv4/4 mice was significantly lower than
that observed from control mice, suggesting that a component of
the glutamate exocytosis was strictly dependent on the presence
of mGlu1 receptors in nerve terminals (Rossi et al., 2013).
It is known that mGlu receptors possess a typical structure
that is typified by the presence of the extracellular Venus Fly
Trap (VFT) domain. This sequence can exist in both the open
and the closed conformations and the shift from one to the
other conformation dictates the receptor activity. The closed
conformation occurs when the orthosteric agonist binds to the
VFT of the receptor subunit, allowing the coupling to the G
protein and the metabolic signaling. In recent years, studies have
shown that the VFT domain of the mGlu1 receptor can adopt the
closed conformation also in the absence of the orthosteric agonist
(De Blasi et al., 2001). In this form, the receptor can trigger the G
protein-mediated cascade of events.
In an attempt to give a rationale for the inhibitory effect
exerted by CPCCOEt on the depolarization-evoked release
of glutamate, Rossi et al. (2013) proposed that in cerebellar
terminals mGlu1 receptors located in glutamatergic terminals
can spontaneously adopt the closed conformation influencing
glutamate exocytosis. If this is the case, one might conclude that
the constitutively activated conformation of receptors in nerve
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endings is retained by particles isolated ex vivo and became
detectable in “in vitro” studies. This aspect is particularly relevant
and deserves further studies.
Presynaptic Release-Regulating mGlu1
Autoreceptors in Mouse Spinal Cord
Nerve Endings
At the spinal cord level, activation of group I mGlu receptors
has been proposed to favor glutamate release, then contributing
to nociceptive plasticity and excitotoxic events that follow spinal
cord injury (Lefebvre et al., 2000; Mills et al., 2001; Lorrain et al.,
2002). The mGlu5 receptor subtype was proposed to play the
major role in these events (Hu et al., 2007; Hu and Gereau,
2011), but the participation of mGlu1 receptor subtypes was not
excluded (Mills et al., 2001).
In order to address the question of whether mGlu5/1
heteroreceptors exist in spinal cord glutamatergic terminals
and their relative contribution to the control of glutamate
release, Giribaldi et al. (2013) monitored the spontaneous
release of this transmitter from mouse spinal cord glutamate
nerve endings that were exposed in superfusion to the group
I mGlu receptor agonist 3,5-DHPG. Differently from all the
other CNS regions so far described, the authors found that
the spontaneous release of glutamate (measured as release of
preloaded [3H]D-aspartate) from synaptosomes isolated from the
entire spinal cord was significantly potentiated by 0.3–30 µM 3,5-
DHPG. As already discussed (see Presynaptic Release-Regulating
mGlu1 Autoreceptors in Mouse Cortical Nerve Endings), the
observation that activation of metabotropic receptors positively
coupled to PLC translocation and membrane PI can elicit
glutamate release implies that the Ca2+ ions mobilization from
the intraterminal stores that follows the activation of these
receptors is sufficient enough to trigger transmitter exocytosis
(see Longordo et al., 2006; Musante et al., 2008a). Accordingly,
exposure of spinal cord synaptosomes to the mGlu1/5 agonist
elicited an over-production of IP3, which was paralleled by a
significant mobilization of Ca2+ ions in the cytosol. Inasmuch,
blockade of the IP3-sensitive receptors with Xestospongin-C
prevented the releasing activity (Giribaldi et al., 2013). The
existence of mGlu1 and mGlu5 receptor proteins in glutamatergic
nerve endings was further supported by immunochemical studies
showing that synaptosomal lysate were positive for mGlu1 and
mGlu5 immunostaining and that mGlu1 and mGlu5 positivity in
synaptosomes was co-expressed with VGlut1 immunoreactivity
(Giribaldi et al., 2013). The 3,5-DHPG-induced facilitation
of glutamate outflow was largely prevented either by the
mGlu1 receptor antagonist CPCCOEt or by the mGlu5 receptor
antagonist MPEP, although the two inhibitory effects were not
additive when the antagonists were added concomitantly.
The finding that either the selective mGlu1 or the mGlu5
receptor antagonists could prevent the 3,5-DHPG-induced
facilitation of glutamate release, suggests that the facilitation
of glutamate exocytosis lays on the activation of both
receptor subtypes, which are possibly functionally coupled
in a heterodimeric assembly or in a dimeric association
of dimers. Actually, as already discussed (see Presynaptic
Release-Regulating mGlu1 Autoreceptors in Mouse Cortical
Nerve Endings), the occupancy of one orthosteric binding
site by an agonist in a heterodimeric assembly is expected
to modify the second orthosteric binding site. Whatever the
receptor organization (mGlu1/mGlu5 heterodimeric assembly
or association of mGlu1 and mGlu5 homodimers) it might be
predicted that glutamate acting at one receptor subtype should
interfere with the binding of the agonist at the hortosteric
binding site of the complementary receptor protein, as indeed
observed, then controlling the receptor-mediated events. This
kind of mGlu1/mGlu5 receptor/receptor interaction does not
represent a novelty. Actually, previous studies had shown that
mGlu1 and mGlu5 receptors could be mutually exclusive in cells
(Benquet et al., 2002) and in nerve terminals (Feligioni et al.,
2003).
MGLU1 HETERORECEPTORS IN
CENTRAL NERVOUS SYSTEM
Presynaptic mGlu1 Heteroreceptors and
GABA Release from Mouse Cortical and
Hippocampal Nerve Endings
The existence and the functional role of mGlu1 heteroreceptors
controlling GABA release in distinct CNS regions (i.e., in the
cortex and in the hippocampus) have been largely debated
and their involvement still remains undocumented. It had
been shown that selective mGlu1 receptor antagonists are
neuroprotective, since they enhance GABAergic transmission in
the hippocampus (Battaglia et al., 2001; Pellegrini-Giampietro,
2003; Ferraguti et al., 2008). The mechanism underlying the
control of GABA release was proposed not to involve the
activation of mGlu1 receptors located on GABAergic nerve
terminals, but rather was suggested to depend on an indirect
cascade of events leading to a reduced activation of inhibitory
CB1 receptors controlling GABA exocytosis. It has been further
proposed that the blockade of mGlu1 receptors leads to a
reduced production of DAG, (i.e., the second messenger that
could be enzymatically transformed into the endogenous acyl-
glycerol 2), one of the endogenous agonists at cannabinoid
receptors. Blockade of mGlu1 receptors, therefore, might lead
to a reduced production of the endocannabinoid, diminishing
the probability that the inhibitory CB1 receptors located on
GABAergic nerve terminals could be activated (Pellegrini-
Giampietro, 2003; Ferraguti et al., 2008). If this is the case, the
CB1-mediated inhibitory signaling on GABAergic terminals is
diminished, favoring therefore GABA release. Well in line with
the hypothesis of an indirect mGlu1-mediated control of GABA
exocytosis, it was shown that 3,5-DHPG cannot modify neither
the spontaneous nor the KCl-evoked release of endogenous
GABA or preloaded [3H]GABA from nerve terminals isolated
from the cortex and the hippocampus of adult mice (Musante
et al., 2010; Zucchini et al., 2013). Inasmuch, it was demonstrated
that both CPCCOEt and MPEP also were unable to modify
the release of GABA from both synaptosomal preparations,
ruling out the possibility that mGlu1 and mGlu5 receptors
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adopting the constitutively activated form are not present on
these terminals.
Presynaptic mGlu1 Heteroreceptors and
Glycine Release in Rodent Central
Nervous System
Besides GABA, glycine has a main inhibitory role in CNS of
mammals, and it participates in the control of nociception
and the processing of pain. De Novellis et al. (2002) provided
evidence of the role of mGlu1 receptors to control the release of
glycine at the periaqueductal level in awake, freely moving rats.
In this study, brain microdialysis experiments were performed
to investigate the impact of mGlu receptors ligands on the
bioavailability of glycine in dialysate samples. The authors
provided clearly evidence that activation of mGlu1 receptors
account for the increased release of glycine in the periaqueductal
gray (PAG) nucleus. The exact location of these receptors
remains, however, to be established.
Presynaptic mGlu1 Heteroreceptors and
Acetylcholine Release from Human
Cortical Nerve Endings
The existence of mGlu1 heteroreceptors on cholinergic terminals
has been scarcely investigated. The data available in the literature
originate from studies aimed at clarifying the impact of the HIV-1
viral protein Tat on central neurotransmission in mammal CNS.
The viral protein was reported to affect both the spontaneous
and the depolarization-evoked release of selected transmitters
(i.e., noradrenaline, glutamate, GABA, and acetylcholine, Neri
et al., 2007) from nerve terminals isolated from rodents and
human CNS (Feligioni et al., 2003; Longordo et al., 2006). In
most cases, the control of transmitter outflow exerted by the
viral protein was found to involve the mGlu receptors belonging
to the group I. In particular, as the release of acetylcholine is
concerned, it was demonstrated that activation of both mGlu1
and mGlu5 heteroreceptors underlies the Tat-induced releasing
activity in human cortical cholinergic nerve endings. This
conclusion relied on the finding that the Tat-releasing activity was
efficiently abrogated by CPCCOEt as well as by MPEP. The two
antagonists efficiently abrogated on their own the Tat-mediated
releasing activity, but the antagonism did not further increase
when they were added concomitantly, which is compatible with
the idea that the two receptors were reciprocally exclusive in
controlling acetylcholine outflow. The results obtained with the
antagonists support the idea that the receptors co-localize on
the same terminal and their signaling converge and control
a common intraterminal pathway (see Presynaptic Release-
Regulating mGlu1 Autoreceptors in Mouse Spinal Cord Nerve
Endings). In line with the prediction that mGlu1/5 receptor(s)
exist in human cortical cholinergic nerve endings, 3,5-DHPG
mimicked Tat in promoting acetylcholine release as well as the
endogenous IP3 production. Both events were prevented when
both CPCCOEt and MPEP were added independently (Feligioni
et al., 2003). In an attempt to propose an animal model suitable
to study the mGlu1/5 heteroreceptors controlling acetylcholine
release, the possibility that Tat and 3,5-DHPG could evoke the
release of [3H]ACh from rodent cortical nerve endings was also
investigated (Feligioni et al., 2003). Unexpectedly, Tat, but not
3,5-DHPG, elicited a marked release of the transmitter in this
synaptosomal preparation. The Tat-evoked [3H]ACh release was
insensitive to mGlu1/5 receptor antagonist, and it did not involve
the binding of endogenous IP3 at the IP3 receptors located
on the endoplasmic reticulum. Altogether these observations
led to the conclusion that receptors other than mGlu1/5 ones,
coupled to different intraterminal pathways, account for the
releasing activity of the viral protein in rodent terminals. To
conclude, these observations led to propose that mGlu1 and
mGlu5 heteroreceptors exist on human cholinergic cortical nerve
terminals. These receptors elicit an IP3-mediated mobilization of
Ca2+ sufficient to trigger the exocytotic-like release of preloaded
[3H]ACh. Based on the results obtained with selective group I
mGlu antagonist, it seems therefore possible to postulate that
the two receptor subtypes (mGlu1 and mGlu5 receptors) are
colocalized on the same terminals and cooperate to release
preloaded [3H]ACh. The expression of these receptors appears
to be species-specific, since the releasing activity exerted by
3,5-DHPG could not be replicated in rodent cortical nerve
endings. Notably, mGlu1 and mGlu5 receptors were also reported
to regulate the excitability of cholinergic interneurons in the
striatum (Bonsi et al., 2008). Whether the two receptors colocalize
or they exist on different neurons was not elucidated, but
they were found to differently modulate the firing of these
neurons. In particular, mGlu5 receptors were reported to rapidly
desensitize after repetitive stimulation, while mGlu1-mediated
effects became detectable once mGlu5 receptors were blocked
(Bonsi et al., 2008 and references therein). Further studies are
required to better describe the system.
Presynaptic mGlu1 Heteroreceptors and
Noradrenaline Release from Human and
Rat Nerve Endings
The majority of noradrenergic terminals and varicosities fail to
make synaptic contacts, although they possess the prerequisites
of transmitter release (i.e., vesicles and mitochondria). They
release the transmitter into the extrasynaptic space that reaches
postsynaptic targets through the volume diffusion. The release
of noradrenaline is controlled by endogenous ligands acting
at receptors located presynaptically on these structures. These
receptors could be either autoreceptors (usually α2 receptors)
or heteroreceptors. Heteroreceptors sense transmitters that reach
noradrenergic boutons by volume diffusion. Among these
heteroreceptors, studies have shown the existence and the
functional role of glutamate receptors (Fink et al., 1989; Pittaluga
and Raiteri, 1990; Pittaluga et al., 1997, 2001, 2005; Grilli et al.,
2009).
As to the mGlu receptors belonging to the first group, their
presence in rat hippocampal noradrenergic nerve terminals
was first addressed by Parodi et al. (2006). The authors
provided functional observations indicating that presynaptic
release-regulating mGluRs of the group I, subtype 5, exist on
noradrenergic axon terminals. The activation of these receptors
with 3,5-DHPG alone cannot elicit a releasing activity. At a first
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glance, the lack of efficacy of 3,5-DHPG in unveiling the release
of preloaded [3H]noradrenaline ([3H]NA) from noradrenergic
particles might suggest that these terminals do not possess group
I mGlu receptors. This conclusion, however, was ruled out by
the observation that a 3,5-DHPG-mediated releasing activity
became evident when synaptosomes were concomitantly exposed
to mild depolarizing stimuli, such as veratrine or nicotine, acting
at nicotine heteroreceptors. Interestingly, in both cases, the 3,5-
DHPG-mediated facilitation of noradrenaline exocytosis was
prevented by MPEP, while CPCCOEt was ineffective, suggesting
that mGlu5 receptors are mainly involved.
The finding that 3,5-DHPG could modulate both events
deserves some comments. Veratrine is an alkaloid that elicits
transmitter exocytosis by activating Na+ channels and by
allowing the opening of the Voltage Operated Calcium Channels
(VOCCs). Nicotine elicits the exocytotic Ca2+-dependent release
of preloaded [3H]NA from rat hippocampal nerve endings by
activating α3β4 and possibly α3β2 nicotinic receptors (nAChRs,
Marchi and Grilli, 2010). Both nAChRs are highly permeable
to Na+ ions, whose influx into synaptosomal particles causes
the depolarization of the synaptosomal plasma membranes and
the consequent activation of VOCCs. The positive effect exerted
by 3,5-DHPG on both depolarizing stimuli, therefore, could
rely on a common cascade of event(s) that triggers additive
increased bioavailability of Ca2+ ions in the cytosol; this in
turn promotes the Ca2+-dependent mechanism of release of
the catecholamine. For instance, by favoring the hydrolysis of
membrane phosphoinositide, mGlu1/5 receptors can promote
the production of endogenous IP3, which then favors the
release of Ca2+ from the IP3-sensitive stores in the endoplasmic
reticulum. Accordingly, the 3,5-DHPG-mediated facilitation of
noradrenaline exocytosis was prevented by Xestospongin-C, a
blocker of the IP3-sensitive receptors.
Assuming that all the noradrenergic nerve terminals in
rat hippocampus are endowed with mGlu5 heteroreceptors,
3,5-DHPG should be expected to reinforce in a MPEP-
sensitive manner the releasing activity elicited by different
Na+-dependent depolarizing stimuli. In line with this
expectation, Luccini et al. (2007a) found that 3,5-DHPG
significantly potentiates the releasing activity elicited by the
activation of NMDA heteroreceptors on rat hippocampal
noradrenergic nerve endings. In this case, however, the effect
of 3,5-DHPG was prevented by the concomitant application
of MPEP and CPCCOEt, while the two antagonists were
inactive when added alone. These observations suggests that:
(i) mGlu1 heteroreceptors also exist on rat hippocampal
FIGURE 4 | Hypothesis on the mGlu1 auto and heteroreceptors assembly in nerve terminals from different CNS regions and their functional
interaction with mGlu5 receptors. The data available in literature suggest that low affinity mGlu1 (green external domains) receptors exist in human and mouse
cortical nerve endings where they are physically linked and functionally coupled to co-localized high affinity mGlu5 (red external domains) autoreceptors. Low affinity
mGlu1 autoreceptors also exist in cerebellar glutamatergic synaptosomes, which adopt a constitutively activated conformation that is retained by isolated cerebellar
synaptosomes. mGlu1 autoreceptors are present in spinal cord glutamatergic nerve endings where they are coupled to mGlu5 autoreceptors in a functional
association that is mutually exclusive. Finally, the existence of mGlu1 autoreceptors in hippocampal glutamatergic nerve endings has been postulated but direct
evidence supporting this notion are not so far available. Further studies are required to better characterize these receptors. As the mGlu1 heteroreceptors are
concerned, evidence demonstrating the existence of mGlu1 receptors on GABAergic terminals is so far lacking. Differently, mGlu1 heteroreceptors exist on human
cholinergic nerve endings. These receptors are coupled to mGlu5 heteroreceptors; the two receptors substitute one for each other and their activation elicits
acetylcholine release. mGlu1/mGlu5 heteroreceptors also exist on human and mouse noradrenergic nerve endings. These receptors are unable on their own to
release the amine but positively control the releasing activity of co-localized NMDA receptors.
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noradrenergic nerve terminals, and (ii) mGlu1 and mGlu5
receptors compensate one for the other in reinforcing the
NMDA-mediated releasing activity. Again, the observation that
the mGluR-induced facilitation of the NMDA-releasing activity
is prevented by a combination of both of the two group I mGlu
antagonists tends to exclude the possibility that the two receptors
exist on different noradrenergic nerve terminals. Differently,
it strongly supports the co-localization of mGlu1 and mGlu5
heteroreceptors on noradrenergic nerve endings bearing NMDA
heteroreceptors. To further complicate the scenario, data in
the literature had shown that nicotine receptors and NMDA
receptors colocalize on rat hippocampal noradrenergic nerve
endings, with the nicotine receptors being permissive to NMDA–
mediated functions in ionic conditions that are expected to
impede NMDA-mediated releasing activity (i.e., in the presence
of Mg2+ ions, Marchi and Grilli, 2010).
Thus, it appears that in noradrenergic terminals an intricate
combination of receptor-receptor functional interactions could
take place, allowing the functional recruitment of different
mGlu receptor subtypes, depending on the depolarizing stimuli
applied. The most conservative hypothesis is that mGlu1 and
mGlu5 receptors localize on distinct regions of the plasma
membranes of rat hippocampal nerve endings, where they can be
differently recruited by local depolarization to interact with co-
localized ionotropic receptors. According to this view, receptors
present in noradrenergic synaptosomal plasma membranes do
not necessary cross-talk, at least by a functional point of view,
with group I mGluRs. It is the case, of the cyclothiazide-sensitive
GluA2-containing AMPA heteroreceptors, which exist on rat
hippocampal noradrenergic nerve endings. Previous studies had
shown that these receptors traffic in-out synaptosomal plasma
membranes in a constitutive manner (Pittaluga et al., 1997,
2005, 2006). Although these receptors are associated to ionic
channels permeable to monovalent cation, their activation did
not unveil the mGlu1/5 receptor-mediated releasing activity,
suggesting that the receptors are not functionally coupled
(Longordo et al., 2006). The low percentage of noradrenergic
nerve endings/varicosities in the rat hippocampal synaptosomal
fraction does not allow biochemical studies aimed at isolating and
identifying the receptor protein localized on this synaptosomal
subpopulation. The hypothesis so far described therefore could
not be confirmed with immunohistochemical investigations.
However, the functional cross-talk bridging NMDA receptors
and mGlu1/5 receptors was also demonstrated to take place in
human neocortical noradrenergic nerve terminals, supporting
the use of the rodent model as a suitable approach to study the
amine transmission in human (Luccini et al., 2007a).
Presynaptic mGlu1 Heteroreceptors and
Dopamine Release from Rat Nerve
Endings
The existence and the role of group I mGlu receptors
in dopaminergic neurones has been largely investigated
and the distribution and role of these receptors has been
described by Conn et al. (2005). mGlu1 receptors were
propose to exist on dopaminergic fibers which converge
with corticostriatal glutamatergic terminals on medium spiny
neurones. Whether these receptors are present in dopaminergic
striatal nerve endings, and if their activation directly modifies
dopamine release, was scarcely investigated. So far, mGlu5 and
mGlu1 heteroreceptors controlling the release of preloaded
[3H]dopamine ([3H]DA) were shown to exist on caudate
putamen synaptosomes preloaded with the tritiated radioactive
tracer. In particular, MPEP and CPCCOEt significantly inhibited
the release of [3H]DA elicited by a mild depolarizing stimulus.
This observation supports the idea that in these terminals both
receptors could have adopted a constitutive active conformation
(Mura et al., 2010). Further studies are, however, required to
address this issue.
CONCLUSION
The present work aimed to review the evidence recently
accumulated in favor of the existence and the role of
presynaptic mGlu1 receptors as modulators for the release of
transmitters from nerve terminals in mammalian CNS. These
data suggest a complex scenario in which mGlu1 receptors
exist on different synaptosomal subpopulations in different
CNS regions. The activation of presynaptic mGlu1 receptors
exerts distinct actions depending on the nerve terminal subtype
involved, but mainly rely on the activation of intraterminal
pathways positively coupled to the hydrolysis of membrane
phosphoinositide. The concomitant application of a mild
depolarizing stimulus is in most cases essential to acquire
the mGlu1-mediated releasing activity. mGlu1 autoreceptors
can adopt a constitutively activated conformation, which
functional role deserves further investigation. mGlu1 receptors
colocalize and are functionally coupled to mGlu5 receptors, by
means of complex interactions that, depending on the nerve
terminals subfamily, make the two receptors mutually exclusive,
mutually compensatory, or independent one from each other.
mGlu1/mGlu5 receptor/receptor interaction is strictly region-
and transmitter- dependent, as summarized in Figure 4. The
receptor models here described represent suitable experimental
paradigm(s) for the study of new agents acting at both the
orthosteric and the allosteric binding sites of mGlu1 receptors,
allowing the advance in the knowledge of their role in patho-
physiological conditions.
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